May 2024 FDA Recall Duloxetine by Golden State Medical Supply Inc.
D-0568-2024 - CGMP Deviations

This Class II drug recall was voluntarily initiated by Golden State Medical Supply Inc. on May 13, 2024 for the product Duloxetine. The FDA reported the reason for recall as cgmp deviations. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-0568-2024

Reason for Recall
CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the proposed interim limit.
Initiated
05-13-2024
Reported
07-03-2024
Quantity
21,655 (30 count bottle), 34,149 (90 count bottle)

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Golden State Medical Supply Inc.
Nationwide in the U.S.
Duloxetine Delayed-Release Capsules, USP, 30mg, Rx Only, a) 30 capsules bottles, NDC 60429-165-30; b) 90 capsules bottles, NDC 60429-165-90, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Packaged by GSMS, Incorporated, Camarillo, CA 93012.

Batch or Lot Expiration Information

Lot# Lot: a) GS045371, Exp: 01/31/2025; b) GS045910, Exp. 01/31/2025